Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003
Retrieved on:
Tuesday, November 29, 2022
IP, FIH, TSX, Multimedia, PCT, United States Patent and Trademark Office, End organ damage, Pain, Safety, Insurance, Physician, Patent Cooperation Treaty, Solubility, Patient, Legislation, Plasma protein binding, Inflammation, Composition, Patent, TBP, News, COVID, Research, HU308, Sepsis, FRA, FDA, Generic drug, Pharmaceutical industry, Tetra
Tetra strengthens its intellectual property position with PCT and provisional patent applications for its innovative therapeutic, ARDS-003.
Key Points:
- Tetra strengthens its intellectual property position with PCT and provisional patent applications for its innovative therapeutic, ARDS-003.
- MONTREAL, Nov. 29, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced the filing of three patent applications for its novel therapeutic, ARDS-003.
- The Company filed a provisional patent application with the United States Patent and Trademark Office related to crystalline Onternabez and uses thereof.
- Guy Chamberland, CEO and Chief Regulatory Officer at Tetra commented "This is a significant step in protecting our novel therapeutic, ARDS-003.